Atea Pharmaceuticals Inc   (AVIR)
Other Ticker:  
Price: $3.6600 $-0.03 -0.813%
Day's High: $3.725 Week Perf: 1.67 %
Day's Low: $ 3.64 30 Day Perf: -0.81 %
Volume (M): 148 52 Wk High: $ 4.69
Volume (M$): $ 543 52 Wk Avg: $3.55
Open: $3.71 52 Wk Low: $2.77

 Market Capitalization (Millions $) 305
 Shares Outstanding (Millions) 83
 Employees 12
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -131
 Cash Flow (TTM) (Millions $) -39
 Capital Exp. (TTM) (Millions $) 0

Atea Pharmaceuticals Inc
Atea Pharmaceuticals Inc, founded in 2014, is a biopharmaceutical company headquartered in Boston, Massachusetts, USA. The company is focused on discovering and developing novel antiviral therapeutics to treat infectious diseases. Their proprietary platform is based on the use of nucleotide prodrugs that target the viral RNA polymerase, a key enzyme essential for viral replication.

Atea Pharmaceuticals is particularly focused on developing antiviral therapies to combat RNA viruses like hepatitis C virus (HCV), respiratory syncytial virus (RSV), and most recently, the novel coronavirus (SARS CoV-2) responsible for COVID-19. The company has built a team of experienced scientists, biotech innovators, and clinical development experts with deep expertise in antiviral drug discovery and development.

Their lead drug candidate, AT-527, is being developed as an oral antiviral therapy for the treatment of influenza and COVID-19. In preclinical studies, AT-527 has demonstrated potent antiviral activity against a broad range of influenza strains and activity against SARS CoV-2 in vitro. The drug has received Fast Track designation from the US FDA for the treatment of COVID-19, and clinical trials are ongoing.

In addition to AT-527, Atea Pharmaceuticals has a pipeline of other antiviral candidates in preclinical development, including compounds for the treatment of RSV and HCV. The company has also established partnerships with leading academic institutions and biotech companies to collaborate on the development of antiviral therapies.

Atea Pharmaceuticals is backed by a group of leading venture capital firms, including Morningside Ventures, Cormorant Asset Management, and RA Capital Management. The company has raised over $500M in funding since its inception and has grown its team to more than 150 employees.

Overall, Atea Pharmaceuticals Inc is a rapidly growing biopharmaceutical company that is committed to developing innovative antiviral therapies to address unmet medical needs and improve patient outcomes.

   Company Address: 225 Franklin Street Boston 2110 MA
   Company Phone Number: 284-8891   Stock Exchange / Ticker: NASDAQ AVIR


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

New Breakthroughs in Hepatitis C Virus Treatment: A Potential Best-in-Class Combination Therapy

Published Wed, May 22 2024 11:00 AM UTC

Hepatitis C virus (HCV) is a major global health concern, with an estimated 71 million people worldwide living with chronic HCV infection. This blood-borne virus can lead to severe liver damage, cirrhosis, and even hepatocellular carcinoma if left untreated. Over the years, significant progress has been made in the development of antiviral therapies, aiming for sustained vir...


Antiviral Pioneer, Atea Pharmaceuticals to Disclose First Quarter Earnings and Business Update on May 14, 2024.?

Published Tue, May 7 2024 11:01 AM UTC

Headquartered in Boston, Massachusetts, Atea specializes in antiviral therapeutics, pushing the boundaries of scientific innovation to meet the dire need in the market for efficacious treatments against grave viral diseases. The conference call comes in the wake of an exciting and productive first quarter for Atea that ended on March 31.This conference call and audio webcast...

Clinical Study

Breakthrough in COVID-19 Treatment: Atea Pharmaceuticals Wraps Up Global Enrollment Phase of Bemnifosbuvir Trials

Published Wed, Mar 27 2024 11:00 AM UTC

Atea Pharmaceuticals has recently reported the completion of patient enrollment in the Phase-3 SUNRISE-3 Trial of Bemnifosbuvir, an oral antiviral medication developed for the treatment of high-risk COVID-19 patients. The global trial observed the enrollment of over 2,200 people, all high-risk individuals, within the Bemnifosbuvir monotherapy cohort. This milestone demonstra...

Clinical Study

Atea Pharmaceuticals Makes Striking Progress: 98% Success in Phase 2 Hepatitis C Study and Major Milestone in Phase 3 Trial for COVID-19

Published Mon, Jan 8 2024 9:05 PM UTC

Atea Pharmaceuticals, a biopharmaceutical company focused on discovering and developing antiviral therapeutics, recently announced positive initial data from a Phase 2 study for Hepatitis C Virus (HCV) and a significant enrollment milestone for their Phase 3 SUNRISE-3 trial for COVID-19. This groundbreaking study showcased a remarkable 98% sustained virologic response at Wee...

Atea Pharmaceuticals Inc

Atea Pharmaceuticals Inc. Releases Impressive Q3 2023 Results, Announced by AVIR

Investors in the Major Pharmaceutical Preparations sector are closely watching the performance of Atea Pharmaceuticals Inc as they interpret its third-quarter 2023 results. The company recently announced an operating shortfall of $-40.785 million for the period from July to September 30, 2023. Notably, Atea Pharmaceuticals Inc has not yet disclosed any revenue figures.
To gain further context, experts are comparing the current performance with that of the third quarter of 2022. During that period, the company reported an operating shortfall of $-16.281 million. It comes as no surprise that the evolving organization experienced a net loss of $-33.142 million, an increase from the $-8.066 million loss reported in the previous fiscal year, which ended on September 30, 2022.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com